Search

Your search keyword '"Kruis, Wolfgang"' showing total 543 results
Start Over Author "Kruis, Wolfgang"
543 results on '"Kruis, Wolfgang"'

155. Are Endoscopic Endpoints Reliable in Therapeutic Trials of Ulcerative Colitis?

Author

Wolff, Sebastian, Terheggen, Grischa, Mueller, Ralph, Greinwald, Roland, Franklin, Jeremy, Kruis, Wolfgang, Wolff, Sebastian, Terheggen, Grischa, Mueller, Ralph, Greinwald, Roland, Franklin, Jeremy, and Kruis, Wolfgang

Abstract

Background:The consistency of endoscopic and histologic findings in patients with ulcerative colitis (UC) has not been elucidated. Choice of assessment may affect study outcomes.Methods:Post hoc analyses were performed using data from 2 randomized, controlled multicenter trials: (1) SAG-26, mesalazine granules for induction of remission in UC (n = 380), and (2) SAG-27, mesalazine granules for maintenance of UC remission (n = 647). Assessments included Clinical Activity Index, Endoscopic Index, modified Disease Activity Index, and Histology Index.Results:In SAG-26, 52 of 380 patients (13.7%) with clinically (Clinical Activity Index >4) and endoscopically (Endoscopic Index 4) active UC showed no histological signs of active inflammation (Histology Index 1) at baseline. Among endoscopically and histologically active patients, 246 of 327 (75.2%) reached clinical remission versus 48 of 52 patients (92.3%) with active endoscopy but no inflammation on histology (difference, 17.1%; P = 0.006). The difference in the proportion of patients achieving clinical remission according to endoscopy and histology in clinically inactive (Clinical Activity Index 4) patients was 30.8% in SAG-26 (at the study end) and 28.1% in SAG-27 (at baseline). In SAG-27, clinical relapse occurred in 21.2% of patients with endoscopic and histologic remission at baseline and 27.1% of patients with some histological inflammation at baseline (P = 0.111). Using the modified Disease Activity Index 1 (mucosal healing) instead of the Endoscopic Index score, the difference was similar (21.2% versus 28.0%, P = 0.073).Conclusions:Endoscopic and histologic assessments differ in both active and inactive UC. Overdiagnosis of inflammation using endoscopy versus histology can significantly affect outcomes, at least in studies using induction of clinical remission as an endpoint. The assessment criteria for trials in UC should be reconsidered.

Published
2013

159. 808 Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial of Mesalamine for the Prevention of Recurrence of Diverticulitis

Author

Kruis, Wolfgang, primary, Eisenbach, Thomas, additional, Löhr, Hanns, additional, Müser, Moritz, additional, Tan, Gie T., additional, Lukas, Milan, additional, Vich, Tomás, additional, Bunganic, Ivan, additional, Pokrotnieks, Juris, additional, Derova, Jelena, additional, Kondrackiene, Jurate, additional, Safadi, Rifaat, additional, Tuculanu, Daniel, additional, Tulassay, Zsolt, additional, Banai, János, additional, Dilger, Karin, additional, Greinwald, Roland, additional, Mohrbacher, Ralf, additional, and Spiller, Robin C., additional

Published
2013
Full Text
View/download PDF

164. A Global Perspective on Irritable Bowel Syndrome

Author

Quigley, Eamonn M. M., primary, Abdel-Hamid, Hussein, additional, Barbara, Giovanni, additional, Bhatia, Shobna J., additional, Boeckxstaens, Guy, additional, De Giorgio, Roberto, additional, Delvaux, Michel, additional, Drossman, Douglas A., additional, Foxx-Orenstein, Amy E., additional, Guarner, Francisco, additional, Gwee, Kok-Ann, additional, Harris, Lucinda A., additional, Hungin, A. Pali S., additional, Hunt, Richard H., additional, Kellow, John E., additional, Khalif, Igor L., additional, Kruis, Wolfgang, additional, Lindberg, Greger, additional, Olano, Carolina, additional, Moraes-Filho, Joaquim P., additional, Schiller, Lawrence R., additional, Schmulson, Max, additional, Simrén, Magnus, additional, and Tzeuton, Christian, additional

Published
2012
Full Text
View/download PDF

171. Preface

Author

Kruis, Wolfgang, primary, Spiller, Robin C., additional, Papagrigoriadis, Savvas, additional, Engel, Alexander, additional, and Kreis, Martin E., additional

Published
2012
Full Text
View/download PDF

176. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohnʼs disease

Author

Holtmeier, Wolfgang, primary, Zeuzem, Stefan, additional, Prei, Jan, additional, Kruis, Wolfgang, additional, Böhm, Stephan, additional, Maaser, Christian, additional, Raedler, Andreas, additional, Schmidt, Carsten, additional, Schnitker, Jörg, additional, Schwarz, Joachim, additional, Zeitz, Martin, additional, and Caspary, Wolfgang, additional

Published
2011
Full Text
View/download PDF

179. Significant Differences Between Crohn’s Disease and Ulcerative Colitis Regarding the Impact of Body Mass Index and Initial Disease Activity on Responsiveness to Azathioprine: Results from a European Multicenter Study in 1,176 Patients

Author

Holtmann, Martin H., primary, Krummenauer, Frank, additional, Claas, Christina, additional, Kremeyer, Kristina, additional, Lorenz, Dirk, additional, Rainer, Olivia, additional, Vogel, Iris, additional, Böcker, Ulrich, additional, Böhm, Stephan, additional, Büning, Carsten, additional, Duchmann, Rainer, additional, Gerken, Guido, additional, Herfarth, Hans, additional, Lügering, Norbert, additional, Kruis, Wolfgang, additional, Reinshagen, Max, additional, Schmidt, Jan, additional, Stallmach, Andreas, additional, Stein, Jürgen, additional, Sturm, Andreas, additional, Galle, Peter R., additional, Hommes, Daan W., additional, D’Haens, Geert, additional, Rutgeerts, Paul, additional, and Neurath, Markus F., additional

Published
2009
Full Text
View/download PDF

183. T1124 Once Daily 3g Mesalamine Is the Optimal Dose for Maintaining Clinical Remission in Ulcerative Colitis: A Double-Blind, Double-Dummy, Randomized, Controlled, Dose-Ranging Study

Author

Kruis, Wolfgang, primary, Jonaitis, Laimas, additional, Pokrotnieks, Juris, additional, Acute, Gitana, additional, Mikhailova, Tatyana L., additional, Horynski, Marek, additional, Bátovský, Marian, additional, Rácz, István, additional, Kull, Karin, additional, Faszczyk, Mark, additional, Greinwald, Roland, additional, and Mueller, Ralph, additional

Published
2008
Full Text
View/download PDF

184. 6-Thioguanine Nucleotide–Adapted Azathioprine Therapy Does Not Lead to Higher Remission Rates Than Standard Therapy in Chronic Active Crohn Disease: Results from a Randomized, Controlled, Open Trial

Author

Reinshagen, Max, primary, Schütz, Ekkehard, primary, Armstrong, Victor W, primary, Behrens, Christoph, primary, von Tirpitz, Christian, primary, Stallmach, Andreas, primary, Herfarth, Hans, primary, Stein, Jürgen, primary, Bias, Peter, primary, Adler, Guido, primary, Shipkova, Maria, primary, Kruis, Wolfgang, primary, Oellerich, Michael, primary, and von Ahsen, Nicolas, primary

Published
2007
Full Text
View/download PDF

186. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.

Author

Karmiris, Konstantinos, Bossuyt, Peter, Sorrentino, Dario, Moreels, Tom, Scarcelli, Antonella, Legido, Jesus, Dotan, Iris, Naismith, Graham D., Jussila, Airi, Preiss, Jan C., Kruis, Wolfgang, Li, Andy C. Y., Bouguen, Guillaume, Yanai, Henit, Steinwurz, Flavio, Katsanos, Konstantinos H., Subramaniam, Kavitha, Tarabar, Dino, Zaganas, Ioannis V., and Ben-Horin, Shomron

Abstract

Background and aims: Cerebrovascular accidents [CVA] have rarely been reported in inflammatory bowel disease [IBD] patients treated with anti-tumour necrosis alpha [anti-TNF alpha] agents. Our aim here was to describe the clinical course of CVA in these patients. Methods: This was a European Crohn's and Colitis Organisation [ECCO] retrospective observational study, performed as part of the CONFER [COllaborative Network For Exceptionally Rare case reports] project. A call to all ECCO members was made to report on IBD patients afflicted with CVA during treatment with anti-TNF alpha agents. Clinical data were recorded in a standardised case report form and analysed for event association with anti-TNF alpha treatment. Results: A total of 19 patients were identified from 16 centres: 14 had Crohn's disease, four ulcerative colitis and one IBD colitis unclassified [median age at diagnosis: 38.0 years, range: 18.6-62.5]. Patients received anti-TNF alpha for a median duration of 11.8 months [range: 0-62] at CVA onset; seven had previously been treated with at least one other anti-TNF alpha agent. Complete neurological recovery was observed in 16 patients. Anti-TNF alpha was discontinued in 16/19 patients. However, recurrent CVA or neurological deterioration was not observed in any of the 11 patients who received anti-TNF alpha after CVA [eight resumed after temporary cessation, three continued without interruption] for a median follow-up of 39.8 months [range: 5.6-98.2]. Conclusion: These preliminary findings do not unequivocally indicate a causal role of anti-TNF alpha in CVA complicating IBD. Resuming or continuing anti-TNF alpha in IBD patients with CVA may be feasible and safe in selected cases, but careful weighing of IBD activity versus neurological status is prudent. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

187. The effect of body weight on the severity and clinical course of ulcerative colitis.

Author

Stabroth-Akil, Denia, Leifeld, Ludger, Pfützer, Roland, Morgenstern, Julia, and Kruis, Wolfgang

Subjects
ULCERATIVE colitis, BODY weight, PANCREATITIS, FATTY liver, CROHN'S disease, OBESITY, BODY mass index, CHI-squared test
Abstract

Purpose: Obesity is a risk factor for inflammatory diseases such as nonalcoholic steatohepatitis, pancreatitis, and Crohn's disease. The effect of being overweight or obese on the severity and clinical course of ulcerative colitis (UC) was assessed in a retrospective analysis of data from 2000-2006. Methods: Two hundred and two consecutive UC patients were categorized according to body mass index (BMI). Patient and disease characteristics were compared between BMI categories using chi-square or Kruskal-Wallis tests. The percentage of patients with active UC, complications, steroid therapy, or immunosuppressive therapy was calculated for each group, and matched pair analyses were performed. Results: Ten patients (5 %) were underweight, 111 (55 %) were normal weight, 54 (26.7 %) were overweight, and 27 (13.4 %) were obese. Pancolitis was inversely related to weight. BMI was also inversely correlated to disease severity, with a significantly smaller proportion of years with chronic active disease among overweight subjects versus normal-weight subjects (17.6 versus 23.9 %, p = 0.05). More overweight than normal-weight patients had no chronic active disease in any year (66 versus 49 %, p = 0.06), and the proportion of years with disease complications was higher in normal weight than in overweight subjects (1.8 versus 0.4 %, p = 0.08). Disease activity during 2000-2006 was higher for underweight versus normal-weight patients, and only 20 % of underweight subjects had no hospital admission compared to 80 % of normal-weight patients ( p = 0.07). Conclusions: This first study to explore the influence of obesity on UC showed that high BMI had rather a favorable effect on the prognosis, whereas low BMI pointed to a more severe course of the disease. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

190. Long-Term Effectiveness of Azathioprine in IBD Beyond 4 Years: A European Multicenter Study in 1176 Patients

Author

Holtmann, Martin H., primary, Krummenauer, Frank, additional, Claas, Christina, additional, Kremeyer, Kristina, additional, Lorenz, Dirk, additional, Rainer, Olivia, additional, Vogel, Iris, additional, Böcker, Ulrich, additional, Böhm, Stephan, additional, Büning, Carsten, additional, Duchmann, Rainer, additional, Gerken, Guido, additional, Herfarth, Hans, additional, Lügering, Norbert, additional, Kruis, Wolfgang, additional, Reinshagen, Max, additional, Schmidt, Jan, additional, Stallmach, Andreas, additional, Stein, Jürgen, additional, Sturm, Andreas, additional, Galle, Peter R., additional, Hommes, Daan W., additional, D’Haens, Geert, additional, Rutgeerts, Paul, additional, and Neurath, Markus F., additional

Published
2006
Full Text
View/download PDF

192. Association of Inosine Triphosphatase 94C>A and Thiopurine S-Methyltransferase Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study

Author

von Ahsen, Nicolas, primary, Armstrong, Victor W, primary, Behrens, Christoph, primary, von Tirpitz, Christian, primary, Stallmach, Andreas, primary, Herfarth, Hans, primary, Stein, Jürgen, primary, Bias, Peter, primary, Adler, Guido, primary, Shipkova, Maria, primary, Oellerich, Michael, primary, Kruis, Wolfgang, primary, and Reinshagen, Max, primary

Published
2005
Full Text
View/download PDF

194. A Prospective Evaluation of the Association Between Adverse Drug Reactions to Azathioprine Therapy and Polymorphisms in the Gene Encoding Inosine Triphosphate Pyrophosphatase

Author

Armstrong, Victor W, primary, Reinshagen, Max, additional, von Ahsen, Nicolas, additional, Behrens, Christoph, additional, Shipkova, Maria, additional, von Tirpitz, Christian, additional, Malchow, Helmut, additional, Stallmach, Andreas, additional, Herfath, Hans, additional, Stein, J??rgen, additional, Bias, Peter, additional, Adler, Guido, additional, Kruis, Wolfgang, additional, and Oellerich, Michael, additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results